KR20220130249A - Egfr 억제제 화합물 - Google Patents
Egfr 억제제 화합물 Download PDFInfo
- Publication number
- KR20220130249A KR20220130249A KR1020227031434A KR20227031434A KR20220130249A KR 20220130249 A KR20220130249 A KR 20220130249A KR 1020227031434 A KR1020227031434 A KR 1020227031434A KR 20227031434 A KR20227031434 A KR 20227031434A KR 20220130249 A KR20220130249 A KR 20220130249A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/36—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342141P | 2016-05-26 | 2016-05-26 | |
| US62/342,141 | 2016-05-26 | ||
| PCT/US2017/034163 WO2017205459A1 (en) | 2016-05-26 | 2017-05-24 | Egfr inhibitor compounds |
| KR1020187034187A KR102444835B1 (ko) | 2016-05-26 | 2017-05-24 | Egfr 억제제 화합물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187034187A Division KR102444835B1 (ko) | 2016-05-26 | 2017-05-24 | Egfr 억제제 화합물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220130249A true KR20220130249A (ko) | 2022-09-26 |
Family
ID=60411884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227031434A Ceased KR20220130249A (ko) | 2016-05-26 | 2017-05-24 | Egfr 억제제 화합물 |
| KR1020187034187A Active KR102444835B1 (ko) | 2016-05-26 | 2017-05-24 | Egfr 억제제 화합물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187034187A Active KR102444835B1 (ko) | 2016-05-26 | 2017-05-24 | Egfr 억제제 화합물 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10513509B2 (https=) |
| EP (1) | EP3464275B1 (https=) |
| JP (1) | JP7030066B2 (https=) |
| KR (2) | KR20220130249A (https=) |
| CN (2) | CN112624954A (https=) |
| AR (1) | AR110038A1 (https=) |
| AU (2) | AU2017269335B2 (https=) |
| CA (1) | CA3023176A1 (https=) |
| ES (1) | ES2979136T3 (https=) |
| IL (2) | IL263081B (https=) |
| MX (2) | MX383920B (https=) |
| RU (1) | RU2751341C2 (https=) |
| SG (2) | SG11201809751XA (https=) |
| TW (1) | TWI752033B (https=) |
| WO (1) | WO2017205459A1 (https=) |
| ZA (1) | ZA201807399B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383920B (es) * | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| CN108864079B (zh) * | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | 一种三嗪化合物及其药学上可接受的盐 |
| IL272875B2 (en) | 2017-09-11 | 2023-10-01 | Recurium Ip Holdings Llc | Continuous flow processes for the preparation of bicyclic compounds |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| CN110041302B (zh) * | 2019-03-01 | 2021-11-30 | 南方医科大学 | 2-氨基-4-取代吡啶衍生物及其合成方法和应用 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US20220340547A1 (en) * | 2019-05-22 | 2022-10-27 | Shanghi Hansoh Biosoh Biomedical Co., Ltd. | Indole derivative-containing inhibitor, preparation method therefor and application thereof |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230234941A1 (en) * | 2020-06-23 | 2023-07-27 | Shenzhen Forward Pharmaceuticals Co., Limited. | Salts of Compound and Pharmaceutical Compositions Containing the Same |
| US20240226101A1 (en) * | 2021-04-30 | 2024-07-11 | Suzhou Puhe BioPharma Co., Ltd. | Pyrimidinylaminobenzenes for lung cancer treatment |
| CA3226006A1 (en) * | 2021-07-13 | 2023-01-19 | Korea Research Institute Of Chemical Technology | Novel pyrimidine-2,4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
| EP4403541B1 (en) * | 2021-09-13 | 2026-02-04 | FUJIFILM Corporation | Method for producing halogenobicyclo[1.1.1]pentane |
| AU2023347153A1 (en) * | 2022-09-19 | 2025-05-01 | Advenchen Pharmaceuticals, LLC | Novel pyrimidine compound as kinase inhibitors with biological activities on egfr mutants |
| WO2024094064A1 (en) * | 2022-11-02 | 2024-05-10 | Suzhou Puhe Biopharma Co., Ltd | Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1051350A (en) | 1910-02-02 | 1913-01-21 | Thomas Nogier | Apparatus for the sterilization of liquids. |
| DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| ATE337312T1 (de) | 2001-07-03 | 2006-09-15 | Vertex Pharma | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| US7396940B2 (en) | 2003-10-23 | 2008-07-08 | Hoffmann-La Roche Inc. | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| WO2006026754A2 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| WO2006096564A1 (en) | 2005-03-04 | 2006-09-14 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| US20100267707A1 (en) | 2006-06-22 | 2010-10-21 | Merck Sharp & Dohme Corp. | Tyrosine Kinase Inhibitors |
| WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| AU2008248186B2 (en) | 2007-05-07 | 2014-02-06 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| JP2010031249A (ja) | 2008-06-23 | 2010-02-12 | Sumitomo Chemical Co Ltd | 組成物及び該組成物を用いてなる発光素子 |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス， インコーポレイテッド | Ｐｉ３キナーゼインヒビターおよびその使用 |
| KR101116234B1 (ko) | 2009-10-29 | 2014-03-06 | (주)퓨쳐켐 | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| ES2552462T3 (es) | 2010-10-14 | 2015-11-30 | Jw Pharmaceutical Corporation | Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo |
| MX2013010513A (es) | 2011-03-16 | 2013-10-07 | Hoffmann La Roche | Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos. |
| CN103608014A (zh) | 2011-03-24 | 2014-02-26 | 罗楹 | 激酶抑制剂在治疗和预防炎症疾病中的用途 |
| EP4119551A1 (en) * | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| CN103508961B (zh) | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| MX361088B (es) | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| BR112015027114B1 (pt) | 2013-04-29 | 2021-12-21 | Chong Kun Dang Pharmaceutical Corp | Compostos inibidores seletivos de histona desacetilase e seu uso |
| US20180057603A1 (en) | 2013-08-09 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers |
| EA034866B1 (ru) | 2013-08-30 | 2020-03-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Замещенные пиримидиновые ингибиторы bmi-1 |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| CA2925057A1 (en) | 2013-10-01 | 2015-04-09 | Simon T. BARRY | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| CN104761544B (zh) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| WO2015112705A2 (en) | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN104876914B (zh) | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
| CN104892585B (zh) | 2014-03-06 | 2018-07-03 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| HUE055747T2 (hu) | 2014-04-04 | 2021-12-28 | Astrazeneca Ab | EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| WO2015175965A1 (en) | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
| WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| EP3778584A1 (en) * | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| SMT202000265T1 (it) | 2014-07-11 | 2020-07-08 | Genmab As | Anticorpi che legano axl |
| CN105254615B (zh) | 2014-07-11 | 2017-02-22 | 杭州华东医药集团新药研究院有限公司 | 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途 |
| CN105315285B (zh) | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| WO2016024185A1 (en) * | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| CN104140418B (zh) | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途 |
| WO2016023822A1 (en) | 2014-08-15 | 2016-02-18 | Boehringer Ingelheim International Gmbh | Afatinib pharmaceutical kit for cancer treatment |
| CN106458969A (zh) | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| JPWO2016032003A1 (ja) | 2014-08-30 | 2017-07-13 | 国立大学法人金沢大学 | 肺癌患者用治療剤及び肺癌患者治療の有効性の予測検査方法 |
| WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| EP3191128A4 (en) | 2014-09-11 | 2018-03-14 | Celldex Therapeutics, Inc. | Uses of anti-her3 antibodies for treating cancer |
| CA2962476C (en) | 2014-09-26 | 2023-09-26 | Hi-Stem Ggmbh | Novel methods for sub-typing and treating cancer |
| CN105461695B (zh) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105237515B (zh) | 2014-10-10 | 2018-06-05 | 益方生物科技（上海）有限公司 | 氘代嘧啶类化合物、其制备方法、药物组合物和用途 |
| WO2016054987A1 (zh) * | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| WO2016090174A1 (en) | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| JP6709786B2 (ja) | 2014-12-11 | 2020-06-17 | ベータ ファーマ，インコーポレイテッド | Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体 |
| US20180193274A1 (en) | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
| US20180271853A1 (en) | 2015-01-09 | 2018-09-27 | Metastat, Inc. | Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant III |
| WO2016112302A1 (en) | 2015-01-09 | 2016-07-14 | Metastat, Inc. | Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor |
| EP3255042B1 (en) | 2015-02-04 | 2020-12-30 | Beyondbio Inc. | Heterocyclic compound and pharmaceutical composition comprising same |
| CN104961731A (zh) | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 |
| CN107250108B (zh) | 2015-02-05 | 2020-11-27 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| CN105985323A (zh) | 2015-02-15 | 2016-10-05 | 宁波文达医药科技有限公司 | 新型表皮生长因子受体抑制剂及其应用 |
| EP3265562A4 (en) | 2015-03-05 | 2018-12-19 | TrovaGene, Inc. | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids |
| CN106138061B (zh) | 2015-04-03 | 2019-06-04 | 中国人民解放军第三军医大学第三附属医院 | 预防或减弱肺纤维化的复合物及其制剂和用途 |
| CN106138020A (zh) | 2015-04-03 | 2016-11-23 | 中国人民解放军第三军医大学第三附属医院 | 双胍类药物在制备预防或减弱肺纤维化的药物中的应用 |
| WO2016164217A1 (en) | 2015-04-09 | 2016-10-13 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| CN104844580B (zh) | 2015-04-17 | 2017-10-20 | 中国药科大学 | 嘧啶类化合物、其制备方法及医药用途 |
| RU2017136709A (ru) | 2015-04-23 | 2019-05-23 | Медиммьюн Лимитед | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr |
| CN104817541B (zh) | 2015-05-11 | 2017-06-16 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
| CN108012529A (zh) | 2015-05-15 | 2018-05-08 | 诺华股份有限公司 | 治疗egfr突变的癌症的方法 |
| DK3297438T3 (da) | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| WO2016191471A1 (en) | 2015-05-27 | 2016-12-01 | Metastat, Inc. | Method of use for inhibitors of epidermal growth factor receptor variants ii, iii and vi |
| CA2988131A1 (en) | 2015-06-03 | 2016-12-08 | National Yang-Ming University | Therapeutic methods and compositions for treating non-small cell lung cancer |
| US20160355503A1 (en) | 2015-06-04 | 2016-12-08 | Cleave Biosciences, Inc. | NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN104910049B (zh) | 2015-06-16 | 2016-06-29 | 苏州明锐医药科技有限公司 | Azd9291中间体及其制备方法 |
| PL3319993T3 (pl) | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| JP7539760B2 (ja) | 2015-07-17 | 2024-08-26 | パシレックス・ファーマシューティカルズ・インコーポレイテッド | Ｎｍｔ２の後成的なサイレンシング |
| WO2017015363A1 (en) | 2015-07-20 | 2017-01-26 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Ｈｅｒ３抗體 |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| CN107531678B (zh) | 2015-07-24 | 2020-12-22 | 上海海雁医药科技有限公司 | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| CN105001208A (zh) | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | 一种表皮生长因子受体egfr抑制剂及其制备方法与用途 |
| US10980765B2 (en) | 2015-08-14 | 2021-04-20 | Board Of Supervisors Of Louisiana State University | Isothiocyanatostilbenes as a novel method and product for treating cancer |
| CN105153122B (zh) | 2015-08-27 | 2018-07-20 | 上海圣考医药科技有限公司 | [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用 |
| CN106478605A (zh) | 2015-09-02 | 2017-03-08 | 上海页岩科技有限公司 | 嘧啶类化合物、其制备方法和医药用途 |
| CN105126125A (zh) | 2015-09-12 | 2015-12-09 | 复旦大学 | 一种氧化锌-钆-药物复合纳米粒子及其制备方法和应用 |
| JP6767491B2 (ja) | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| US10308658B2 (en) | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| US20170115275A1 (en) | 2015-10-23 | 2017-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development |
| WO2017075367A1 (en) | 2015-10-28 | 2017-05-04 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN106674202A (zh) | 2015-11-05 | 2017-05-17 | 惠州信立泰药业有限公司 | 化合物a的二甲磺酸盐及其晶型和含有该盐的药物组合物 |
| CN106699736A (zh) | 2015-11-17 | 2017-05-24 | 惠州信立泰药业有限公司 | 化合物A甲磺酸盐的晶型γ和含有该晶型的药物组合物 |
| CN105461729B (zh) | 2015-11-18 | 2017-12-05 | 乳源瑶族自治县大众药品贸易有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
| CN105294717B (zh) | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
| RU2603960C1 (ru) | 2015-11-19 | 2016-12-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака |
| RU2606949C9 (ru) | 2015-11-19 | 2018-03-14 | ЗАО "Р-Фарм" | Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака |
| CN105348267A (zh) | 2015-12-01 | 2016-02-24 | 中山奕安泰医药科技有限公司 | 合成azd9291中间体的方法 |
| JP6978003B2 (ja) | 2015-12-03 | 2021-12-08 | チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド | 複素環式化合物およびその使用 |
| JP6978002B2 (ja) | 2015-12-03 | 2021-12-08 | チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド | チエノ−ピリミジン誘導体およびその使用 |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| TWI623316B (zh) | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| CN105601620A (zh) | 2015-12-25 | 2016-05-25 | 北京康立生医药技术开发有限公司 | 一种甲磺酸迈瑞替尼的制备方法 |
| CA3009850C (en) | 2015-12-27 | 2020-05-26 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof |
| CN106928150B (zh) | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| EP3400218A4 (en) | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| EP4218739A3 (en) | 2016-01-08 | 2023-08-09 | The Regents of The University of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| CN105646454B (zh) | 2016-01-19 | 2018-05-08 | 浙江大学 | 含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用 |
| TWI745345B (zh) | 2016-02-01 | 2021-11-11 | 瑞典商阿斯特捷利康公司 | 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法 |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| CN108601781B (zh) | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| WO2017136774A1 (en) | 2016-02-04 | 2017-08-10 | Stem Cell Theranostics, Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
| CN105585557B (zh) | 2016-02-25 | 2018-06-22 | 清华大学 | 用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
| CN105777716B (zh) | 2016-02-25 | 2018-04-10 | 清华大学 | 一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用 |
| MX383920B (es) * | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| CN105886648A (zh) | 2016-06-06 | 2016-08-24 | 武汉海吉力生物科技有限公司 | 用于检测egfr基因t790m突变的试剂盒 |
| CN106366072B (zh) | 2016-08-19 | 2018-12-07 | 上海工程技术大学 | 一种azd9291的制备方法 |
| CN106366022B (zh) | 2016-08-19 | 2018-03-13 | 上海工程技术大学 | 一种用于制备azd9291的中间体及其制备方法和应用 |
| CN106397407B (zh) | 2016-08-31 | 2018-09-04 | 浙江科聚化工有限公司 | 抗肿瘤药物azd9291衍生物的制备方法 |
| CN106432231B (zh) | 2016-09-09 | 2018-06-12 | 无锡佰翱得生物科学有限公司 | Azd9291的药用盐、及其晶型和制备方法 |
| CN106565522A (zh) | 2016-09-29 | 2017-04-19 | 福格森（武汉）生物科技股份有限公司 | 一种由氟代芳香化合物制备烷氧基芳香化合物的方法 |
| CN106496196B (zh) | 2016-10-20 | 2019-07-02 | 南京雷科星生物技术有限公司 | 一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
| CN106543060B (zh) | 2016-10-31 | 2018-11-06 | 湖南欧亚药业有限公司 | 一种奥斯替尼甲磺酸盐的制备方法 |
| CN106668866A (zh) | 2017-02-13 | 2017-05-17 | 江苏省中医药研究院 | 一种抗非小细胞肺癌的药物组合物及其应用 |
| CN106883216B (zh) | 2017-04-06 | 2020-03-13 | 张家港威胜生物医药有限公司 | 一种奥希替尼的制备方法 |
-
2017
- 2017-05-24 MX MX2018013413A patent/MX383920B/es unknown
- 2017-05-24 WO PCT/US2017/034163 patent/WO2017205459A1/en not_active Ceased
- 2017-05-24 JP JP2018561695A patent/JP7030066B2/ja active Active
- 2017-05-24 EP EP17803481.5A patent/EP3464275B1/en active Active
- 2017-05-24 AU AU2017269335A patent/AU2017269335B2/en active Active
- 2017-05-24 AR ARP170101409A patent/AR110038A1/es unknown
- 2017-05-24 ES ES17803481T patent/ES2979136T3/es active Active
- 2017-05-24 KR KR1020227031434A patent/KR20220130249A/ko not_active Ceased
- 2017-05-24 SG SG11201809751XA patent/SG11201809751XA/en unknown
- 2017-05-24 CA CA3023176A patent/CA3023176A1/en active Pending
- 2017-05-24 CN CN202011563825.6A patent/CN112624954A/zh active Pending
- 2017-05-24 SG SG10202102920QA patent/SG10202102920QA/en unknown
- 2017-05-24 US US15/603,789 patent/US10513509B2/en active Active
- 2017-05-24 CN CN201780032202.6A patent/CN109311858B/zh active Active
- 2017-05-24 RU RU2018138584A patent/RU2751341C2/ru active
- 2017-05-24 KR KR1020187034187A patent/KR102444835B1/ko active Active
- 2017-05-25 TW TW106117475A patent/TWI752033B/zh active
-
2018
- 2018-11-01 MX MX2021007773A patent/MX2021007773A/es unknown
- 2018-11-05 ZA ZA2018/07399A patent/ZA201807399B/en unknown
- 2018-11-18 IL IL263081A patent/IL263081B/en active IP Right Grant
-
2019
- 2019-12-04 US US16/703,544 patent/US11098030B2/en active Active
-
2021
- 2021-03-16 IL IL281537A patent/IL281537A/en unknown
- 2021-08-17 US US17/445,280 patent/US12049460B2/en active Active
- 2021-09-29 AU AU2021240162A patent/AU2021240162A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102444835B1 (ko) | Egfr 억제제 화합물 | |
| AU2015303641B2 (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
| EA024729B1 (ru) | Киназные ингибиторы | |
| NO331925B1 (no) | Substituerte pyrimidiner som proteinkinase-inhibitorer | |
| JP2009526072A (ja) | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 | |
| TW201706272A (zh) | 雙環化合物 | |
| TW202328128A (zh) | Ｃｄｋ７抑制劑及治療癌症之方法 | |
| HK40003936A (en) | Egfr inhibitor compounds | |
| BR112018074232B1 (pt) | Acrilamida n-(3- ((4-(1-(biciclo[1.1.1]pentan-2-il)-1h-indol-3-il)pirimidin-2- il) amino)fenil) substituída e compostos de acrilamida n-(3-((4- (1-(biciclo[1.1.1] pentan-2-il)-1h-indazol-3-il)pirimidin-2- il)amino)fenil) substituída como inibidores de egfr para tratamento de câncer | |
| NZ747854B2 (en) | Egfr inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220908 Application number text: 1020187034187 Filing date: 20181126 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220928 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230328 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230608 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230328 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |